BR9811937A - Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados - Google Patents

Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados

Info

Publication number
BR9811937A
BR9811937A BR9811937-0A BR9811937A BR9811937A BR 9811937 A BR9811937 A BR 9811937A BR 9811937 A BR9811937 A BR 9811937A BR 9811937 A BR9811937 A BR 9811937A
Authority
BR
Brazil
Prior art keywords
bioavailability
increasing
fexofenadine
derivatives
patient
Prior art date
Application number
BR9811937-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Kin-Kai Hwang
Dennis H Giesing
Gail H Hurst
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of BR9811937A publication Critical patent/BR9811937A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/745Polymers of hydrocarbons
    • A61K31/75Polymers of hydrocarbons of ethene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/77Polymers containing oxygen of oxiranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BR9811937-0A 1997-08-14 1998-07-21 Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados BR9811937A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91156397A 1997-08-14 1997-08-14
PCT/US1998/015098 WO1999008690A1 (en) 1997-08-14 1998-07-21 Method of enhancing bioavailability of fexofenadine and its derivatives

Publications (1)

Publication Number Publication Date
BR9811937A true BR9811937A (pt) 2000-09-05

Family

ID=25430473

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811937-0A BR9811937A (pt) 1997-08-14 1998-07-21 Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados

Country Status (29)

Country Link
EP (1) EP1003528B1 (enExample)
JP (1) JP4295913B2 (enExample)
KR (1) KR100522985B1 (enExample)
CN (1) CN1143680C (enExample)
AR (1) AR018505A1 (enExample)
AT (1) ATE224721T1 (enExample)
AU (1) AU725965C (enExample)
BR (1) BR9811937A (enExample)
CA (1) CA2301267C (enExample)
CZ (1) CZ293666B6 (enExample)
DE (1) DE69808303T2 (enExample)
DK (1) DK1003528T3 (enExample)
EE (1) EE04263B1 (enExample)
ES (1) ES2179523T3 (enExample)
HU (1) HU226823B1 (enExample)
ID (1) ID24463A (enExample)
IL (1) IL134521A (enExample)
NO (1) NO325148B1 (enExample)
NZ (1) NZ502133A (enExample)
OA (1) OA11287A (enExample)
PL (1) PL191607B1 (enExample)
PT (1) PT1003528E (enExample)
RU (1) RU2197967C2 (enExample)
SK (1) SK283868B6 (enExample)
TR (1) TR200000419T2 (enExample)
TW (1) TWI240633B (enExample)
UA (1) UA64765C2 (enExample)
WO (1) WO1999008690A1 (enExample)
ZA (1) ZA987221B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ302926A (en) * 1995-02-28 1998-10-28 Hoechst Marion Roussel Inc Composition for use as antihistamines comprising piperidinoalkanol derivatives and inert ingredients
CN1159012C (zh) * 1997-08-26 2004-07-28 阿旺蒂斯制药公司 用于组合哌啶子基烷醇-减充血剂的药物组合物
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
AU2003237253A1 (en) * 2002-05-29 2003-12-19 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
JP2008120684A (ja) * 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
KR101106374B1 (ko) 2009-06-05 2012-01-19 민병욱 고체연료에 의한 가연성 가스 발생 장치
KR101117014B1 (ko) * 2009-09-09 2012-06-14 민병욱 부패성 폐기물의 바이오매스 처리에 의한 폐자원 재활용 방법 및 장치
CN101843616B (zh) * 2010-06-04 2011-07-27 西安万隆制药有限责任公司 一种盐酸非索非那定与微晶纤维素组合物及其制备方法
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
CN103687592A (zh) 2011-05-20 2014-03-26 安万特药物公司 包含非索非那定的药物组合物
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
RU2553362C1 (ru) * 2014-01-09 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ моделирования состояния ингибирования функциональной активности гликопротеина-р линестренолом в эксперименте
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
KR910007515A (ko) * 1989-01-31 1991-05-30 호르스트 카베리쯔 부식에 의한 활성제의 서방형 제제 및 그 제조방법
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
AU5893796A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds

Also Published As

Publication number Publication date
CA2301267A1 (en) 1999-02-25
HU226823B1 (hu) 2009-11-30
PT1003528E (pt) 2003-02-28
JP2001515041A (ja) 2001-09-18
SK1842000A3 (en) 2000-08-14
JP4295913B2 (ja) 2009-07-15
OA11287A (en) 2003-10-22
KR20010022845A (ko) 2001-03-26
NO20000706D0 (no) 2000-02-11
UA64765C2 (uk) 2004-03-15
ZA987221B (en) 1999-02-15
IL134521A (en) 2005-07-25
AU725965C (en) 2004-04-22
IL134521A0 (en) 2001-04-30
DE69808303D1 (de) 2002-10-31
EP1003528B1 (en) 2002-09-25
DK1003528T3 (da) 2003-02-03
AU725965B2 (en) 2000-10-26
ATE224721T1 (de) 2002-10-15
EE200000069A (et) 2000-10-16
CZ293666B6 (cs) 2004-06-16
HK1025901A1 (en) 2000-12-01
PL191607B1 (pl) 2006-06-30
NO325148B1 (no) 2008-02-11
TWI240633B (en) 2005-10-01
DE69808303T2 (de) 2003-05-22
HUP0003189A2 (en) 2001-03-28
RU2197967C2 (ru) 2003-02-10
WO1999008690A1 (en) 1999-02-25
ES2179523T3 (es) 2003-01-16
ID24463A (id) 2000-07-20
NO20000706L (no) 2000-04-13
AU8505098A (en) 1999-03-08
EP1003528A1 (en) 2000-05-31
TR200000419T2 (tr) 2000-09-21
CA2301267C (en) 2004-07-13
CN1143680C (zh) 2004-03-31
AR018505A1 (es) 2001-11-28
HUP0003189A3 (en) 2001-04-28
KR100522985B1 (ko) 2005-10-21
SK283868B6 (sk) 2004-03-02
EE04263B1 (et) 2004-04-15
CN1267221A (zh) 2000-09-20
CZ2000522A3 (cs) 2000-09-13
PL338579A1 (en) 2000-11-06
NZ502133A (en) 2002-03-28

Similar Documents

Publication Publication Date Title
BR9811937A (pt) Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados
WO2001005392A3 (en) Method for treating chronic pain using mek inhibitors
IT1289532B1 (it) Composti, di cloridrato di paroxetina e procedimenti per la loro preparazione
BR9811099A (pt) Inibidores de urocinase
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
BR9813228A (pt) Formulação de 2-metil-tieno-benzodiazepina
ATE195117T1 (de) 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
EE9900441A (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nende solvaatide suu kaudu manustamiseks
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
EE200000522A (et) Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
AU2001249329A1 (en) Lipoxin analogs and methods for the treatment of periodontal disease
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
NO952890L (no) Kombinasjonsbehandling for inhibisjon av bentap
SG44989A1 (en) Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman
DK0998287T3 (da) Anvendelse af levobupivacain
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
DK1468689T3 (da) 2-methyl-thieno-benzodiazepine formulation
KR960006915A (ko) 췌장염의 치료 조성물
PL345510A1 (en) Transdermal plaster containing at least one active ingredient which influences blood serum lipid levels
NZ329839A (en) Combination of a compound which inhibits acetylcholinesterase or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level for treating dementia
DE69625230D1 (de) Thrombininhibitoren
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AOS ARTS. 8O, 13, 24 E 25 DA LPI.

B25D Requested change of name of applicant approved

Owner name: AVENTIS PHARMACEUTICALS INC. (US)

Free format text: ALTERADO DE: HOECHST MARION ROUSSEL, INC.

B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070033918/RJ DE 19/03/2007.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDAS AS ALT. DE NOME E SEDE REQUERIDAS ATRAVES DA PETICAO NO 020080090002/RJ DE 27/06/2008, POR AUSENCIA DE FUNDAMENTACAO LEGAL, UMA VEZ QUE O PEDIDO FOI ARQUIVADO DEFINITIVAMENTE NA RPI 2060 DE 29/06/2010.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO DE TRANSFERENCIA NO 020100076561/RJ DE 18/08/2010, POR AUSENCIA DE FUNDAMENTACAO LEGAL, EM VIRTUDE DO ARQUIVAMENTO DEFINITIVO DO PEDIDO PUBLICADO NA RPI 2060 DE 29/06/2010.

B25B Requested transfer of rights rejected

Owner name: AVENTIS PHARMACEUTICALS INC. (US)

B25B Requested transfer of rights rejected

Owner name: AVENTIS PHARMACEUTICALS INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]